37550 Federal Register / Vol. 65, No. 116 / Thursday, June 15, 2000 / Notices

(‘‘CERCLA’’), 42 U.S.C. 9601 et seq.,

notice is hereby given that a proposed

Agreement and Covenant Not to Sue

associated with the San Fernando

Valley Pollock Superfund was executed

by EPA on April 7, 2000. The proposed

Agreement and Covenant Not to Sue

would resolve certain potential claims

of the United States under sections 106

and 107 of CERCLA, 42 U.S.C. 9606 and

9607, against San Fernando Road

Holdings, LLC. (the ‘‘Purchaser’’). The

Purchaser has acquired certain real

property located at 3332–3340, 3360,

3368, 3370, 3380, 3424 and 3550 San

Fernando Road in the City of Los

Angeles, California (‘‘the Property’’).

The Property consists of approximately

21.48 acres, which is improved with

eight industrial warehouse buildings.

The proposed settlement would require

the Purchaser to pay EPA a one-time

payment of $ 200,000, and to conduct

cleanup activities at the Property under

the direction of the Regional Water

Quality Control Board—Los Angeles

Region.

For thirty (30) calendar days

following the date of publication of this

notice, EPA will receive written

comments relating to the proposed

settlement. EPA’s response to any

comments received will be available for

public inspection at the U.S.

Environmental Protection Agency, 75

Hawthorne Street, San Francisco, CA

94105.

DATES: Comments must be submitted on

or before July 17, 2000.

Availability

The proposed Agreement and

Covenant Not to Sue and additional

background documentation relating to

the settlement are available for public

inspection at the U.S. EPA, Region IX,

75 Hawthorne Street, San Francisco,

CA, 94105. A copy of the proposed

settlement may be obtained from Marie

M. Rongone, Senior Counsel (ORC–3),

Office of Regional Counsel, U.S. EPA

Region IX, 75 Hawthorne Street, San

Francisco, CA, 94105. Comments should

reference ‘‘San Fernando Road

Holdings, LLC Agreement and Covenant

Not to Sue, San Fernando Valley

Pollock Superfund Site,’’ and ‘‘Docket

No. 2000–04’’ and should be addressed

to Ms. Rongone at the above address.

FOR FURTHER INFORMATION CONTACT:

Marie M. Rongone, Senior Counsel

(ORC–3), Office of Regional Counsel,

U.S. EPA Region IX, 75 Hawthorne

Street, San Francisco, CA 94105; E-mail:

rongone.marie@epamail.epa.gov; Phone:

(415) 744–1313; Facsimile (415) 744–

1041.

Dated: May 9, 2000.

Keith Takata,

Director, Superfund Division, U.S. EPA,

Region IX.

[FR Doc. 00–15025 Filed 6–14–00; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION

AGENCY

[OPPTS–42198C; FRL–6494–5]

1,1,2-Trichloroethane (TCE); Final

Enforceable Consent Agreement and

Testing Consent Order

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice.

SUMMARY: Under section 4 of the Toxic

Substances Control Act (TSCA), EPA

has issued a testing consent order

(Order) that incorporates an enforceable

consent agreement (ECA) with The Dow

Chemical Company; Vulcan Materials

Company; Occidental Chemical

Corporation; Oxy Vinyls, LP; Georgia

Gulf Corporation; Westlake Chemical

Corporation; PPG Industries, Inc.;

Borden Chemicals & Plastics Operating

Limited Partnership; and Formosa

Plastics Corporation, U.S.A. (‘‘the

Companies’’). The Companies have

agreed to perform toxicity testing and

physiologically based pharmacokinetics

(PBPK) and mechanistic (MECH) testing

that is intended to satisfy the

toxicological data needs identified in a

proposed test rule for acute toxicity,

subchronic toxicity, developmental

toxicity, reproductive toxicity,

neurotoxicity, carcinogenicity, in vivo

cytogenetics, and immunotoxicity

effects of 1,1,2-trichloroethane (TCE).

This notice announces the ECA and

Order for TCE and summarizes the

terms of the ECA.

DATES: The effective date of the ECA

and Order is June 15, 2000.

FOR FURTHER INFORMATION CONTACT: For

general information contact: Barbara

Cunningham, Director, Office of

Program Management and Evaluation,

Office of Pollution Prevention and

Toxics (7401), Environmental Protection

Agency, 1200 Pennsylvania Ave., NW.,

Washington, DC 20460; telephone

number: (202) 554–1404; e-mail address:

TSCA-Hotline@epa.gov.

For specific information contact: John

Schaeffer, Chemical Control Division

(7405), Office of Pollution Prevention

and Toxics, Environmental Protection

Agency, 1200 Pennsylvania Ave., NW.,

Washington, DC 20460; telephone

number: (202) 260–8130; fax: (202)260–

1096; e-mail address: ccd.citb@epa.gov.

SUPPLEMENTARY INFORMATION: This

notice announces the ECA and Order for

TCE and summarizes the terms of the

ECA.

I. General Information

A. Does this Action Apply to Me?

The ECA and Order announced in this

notice only affect those companies that

signed the ECA for TCE: The Dow

Chemical Company; Vulcan Materials

Company; Occidental Chemical

Corporation; Oxy Vinyls, LP; Georgia

Gulf Corporation; Westlake Chemical

Corporation; PPG Industries, Inc.;

Borden Chemicals & Plastics Operating

Limited Partnership; and Formosa

Plastics Corporation, U.S.A. The

Companies are members of the HAP

Task Force, which is an association of

manufacturers of TCE. However, as a

result of the ECA and Order, EPA has

initiated a rulemaking in the Federal

Register of December 23, 1997 (62 FR

67036) (FRL–5762–9) under TSCA

section 12(b)(1) which, when finalized,

will require all persons who export or

intend to export TCE to comply with the

Agency’s export notification regulations

at 40 CFR part 707, subpart D.

B. How Can I Get Additional

Information, Including Copies of this

Document and Other Related

Documents?

1. Electronically. You may obtain

electronic copies of this document, and

certain other related documents that

might be available electronically, from

the EPA Internet Home Page at http://

www.epa.gov/. To access this

document, on the Home Page select

‘‘Laws and Regulations’’ and then look

up the entry for this document under

the ‘‘Federal Register—Environmental

Documents.’’ You can also go directly to

the Federal Register listings at http://

www.epa.gov/fedrgstr/.

2. In person. The Agency has

established an official record for this

action under docket control number

OPPTS–42198C. The official record

consists of the documents specifically

referenced in this action, any public

comments received during an applicable

comment period, and other information

related to this action, including any

information claimed as Confidential

Business Information (CBI). This official

record includes the documents that are

physically located in the docket, as well

as the documents that are referenced in

those documents. The public version of

the official record does not include any

information claimed as CBI. The public

version of the official record, which

includes printed, paper versions of any

electronic comments submitted during

Federal Register / Vol. 65, No. 116 / Thursday, June 15, 2000 / Notices 37551

an applicable comment period, is

available for inspection in the TSCA

Nonconfidential Information Center,

North East Mall Rm. B–607, Waterside

Mall, 401 M St., SW., Washington, DC.

The Center is open from noon to 4 p.m.,

Monday through Friday, excluding legal

holidays. The telephone number for the

Center is (202) 260–7099.

II. Background

A. What Is TCE?

TCE is used as a feedstock

intermediate in the production of

vinylidene chloride and some

tetrachloroethanes (Ref. 1). It is used as

a solvent where its high solvency for

chlorinated rubbers and other

substances is needed, and for

pharmaceuticals and electronic

components. An estimated 1,036

workers are exposed to TCE. The

Chemical Abstract Service (CAS)

Registry number for TCE is 79–00–5.

B. Why is EPA Requiring Health Effects

Testing on TCE?

EPA proposed health effects testing

under TSCA section 4(a) for a number

of hazardous air pollutants (‘‘HAPs’’ or

‘‘HAPs chemicals’’), including TCE in

the Federal Register of June 26, 1996

(61 FR 33178) (FRL–4869–1), as

amended in the Federal Register of

December 24, 1997 (62 FR 67466) (FRL–

5742–2) and April 21, 1998 (63 FR

19694) (FRL–5780–6). In the HAPs

proposal, the Agency made preliminary

findings for TCE that:

1. TCE may present an unreasonable

risk of injury to health.

2. TCE is or will be produced in

substantial quantities, and there is or

may be substantial human exposure to

the chemical.

3. There are insufficient data to

determine or predict the effects of

activities on human health involving

TCE.

4. Testing is necessary to develop

health effects data for TCE.

See the Federal Register of June 26,

1996 (61 FR 33178, 33190, and 33193)

(FRL–4869–1). See also Ref. 1.

The HAPs rule proposed testing of

TCE for acute toxicity, subchronic

toxicity, developmental toxicity,

reproductive toxicity, neurotoxicity,

carcinogenicity, in vivo cytogenetics,

and immunotoxicity. See the Federal

Register of June 26, 1996 (61 FR 33178

and 33197) (FRL–4869–1) and December

24, 1997 (62 FR 67466 and 67482) (FRL–

5742–2).

III. ECA Development and Conclusion

A. How is EPA Going to Obtain Health

Effects Testing on TCE?

In the proposed HAPs test rule, as

amended, EPA invited the submission

of proposals for pharmacokinetics (PK)

studies for the HAPs chemicals, which

could provide the scientific basis for

alternative testing to the testing

proposed and could provide the basis

for negotiation of ECAs. See the Federal

Register of June 26, 1996 (61 FR 33178

and 33189) (FRL–4869–1) and December

24, 1997 (62 FR 67466 and 67474) (FRL–

5742–2). EPA uses ECAs to accomplish

testing where a consensus is reached

concerning the need for and scope of

testing. The procedures for ECA

negotiations and the criteria for

determining whether a consensus exists

are described at 40 CFR 790.22 and 40

CFR 790.24, respectively.

In response to EPA’s request for

proposals for ECAs, the HAP Task Force

submitted a proposal for alternative

testing involving PK studies for TCE on

November 22, 1996 (Ref. 2). EPA

responded to this proposal by letter on

June 26, 1997 (Ref. 3), indicating that

this approach could offer sufficient

merit to proceed with ECA negotiations.

As a result of the response of the HAP

Task Force on December 12, 1997 (Ref.

4) to EPA’s letter, EPA decided to

proceed with ECA negotiations for TCE.

Consequently, EPA published a

document in the Federal Register of

December 19, 1997 (62 FR 66628) (FRL–

5763–2) soliciting interested parties to

monitor or participate in these

negotiations.

EPA held a public meeting to

negotiate an ECA for TCE on January 12,

1998. The participants reached

agreement on the general scope of the

testing to be required under the ECA,

and the HAP Task Force submitted a

revised proposal for a testing program

on February 27, 1998, which EPA

responded to on September 24, 1998

(Refs. 5,6). A final version of the ECA

was circulated to the HAP Task Force

and returned to EPA for signature. On

June 7, 2000, EPA signed the ECA and

accompanying Order (Ref. 7).

B. What Testing Does the ECA for TCE

Require?

As described in Table 1 of this unit,

this ECA requires the following testing:

1. Tier I HAPs Testing (taken from the

proposed HAPs test rule, as amended):

Acute and subchronic toxicity by the

inhalation route of exposure.

2. Tier I Program Review Testing: The

development of PK/MECH data to

inform route-to-route extrapolation of

data from studies acceptable to EPA that

were performed by a route other than

inhalation and, also, the development

and application of PBPK model

simulations. The PK/MECH data and

PBPK modeling will be subject to

program review by EPA to confirm the

validity of the oral-to-inhalation

extrapolations. This testing relates to the

following endpoints: Neurotoxicity,

developmental toxicity, and

reproductive toxicity (in the rat); and

developmental toxicity,

immunotoxicity, and carcinogenicity (in

the mouse).

3. Tier II Testing and/or Extrapolation

Reporting:

i. Acute neurotoxicity, subchronic

neurotoxicity, developmental toxicity,

and reproductive toxicity testing by the

oral route of exposure.

ii. Route-to-route extrapolation to the

inhalation route for these acute

neurotoxicity, subchronic neurotoxicity,

developmental toxicity, and

reproductive toxicity studies, as well as

for the extant immunotoxicity and

carcinogenicity studies which were also

conducted by the oral route of

administration (Refs. 8,9).

This testing will allow EPA to

characterize certain potential health

hazards resulting from inhalation

exposure to TCE. Table 1 of this unit

sets forth the required testing, test

standards, and reporting requirements

under the ECA for TCE.

In addition, EPA recognizes the

concerns that have been expressed

about animal testing. In this ECA, every

effort is made to avoid unnecessary or

duplicative testing. EPA supports the

goals developed by the Interagency

Coordinating Committee on the

Validation of Alternative Methods

(ICCVAM) (http://iccvam.niehs.nih.gov/

home.htm) to:

1. Encourage the reduction of the

number of animals used in testing.

2. Seek opportunities to replace test

methods requiring animals with

alternative test methods when

acceptable alternative methods are

available.

3. Refine existing test methods to

optimize animal use when there is no

substitute for animal testing. EPA

considers these goals to be important

elements in developing health effects

data for conducting scientifically sound

chemical risk assessments. Thus, where

testing must be conducted to develop

adequate data, the Agency is committed

to reducing the number of animals used

for testing, including, whenever

possible, by incorporating in vitro (nonanimal) test methods or other alternative

approaches that have been scientifically

validated and have received regulatory

acceptance. In addition, in this ECA,

37552 Federal Register / Vol. 65, No. 116 / Thursday, June 15, 2000 / Notices

which involves development of PBPK/

MECH data, the subsequent route-toroute extrapolations to existing datashould result in the use of fewer test

animals as compared to developing all

new data by the inhalation route.

TABLE 1.—REQUIRED TESTING, TEST STANDARDS, AND REPORTING REQUIREMENTS FOR TCE

Testing segment Required testing Test standard Deadline for final

report1 (months)

Tier I HAPs Testing ... Acute toxicity (inhalation) .................. 40 CFR 799.9135 (as annotated in ECA Appendix D.1) ...... 15

Subchronic toxicity (inhalation) .......... 40 CFR 799.9346 (as annotated in ECA Appendix D.2) ...... 24

Tier I Program Review

Testing.

PK/MECH data to support model validation and verification of oral-toinhalation extrapolation for the following data needs in the F344 rat:

a. Neurotoxicity

b. Developmental toxicity

c. Reproductive toxicity

ECA Appendix C (1–3) .......................................................... 15

PK/MECH data to support model development, validation, and

verification of oral-to-inhalation extrapolation for the following data

needs in the mouse:

a. Developmental toxicity

b. Immunotoxicity

c. Carcinogenicity

ECA Appendix C (1–3) .......................................................... 15

PBPK model simulations ................... ECA Appendix C (1–5) .......................................................... 24

Tier II Testing and/or

Extrapolation Reporting.

Acute neurotoxicity (oral) ................... 40 CFR 799.9620 (as annotated in ECA Appendix D.3) ...... 36

Acute neurotoxicity extrapolation of

oral data to inhalation.

ECA Appendix C .................................................................... 39

Subchronic neurotoxicity (oral) .......... 40 CFR 799.9620 (as annotated in ECA Appendix D.3) ...... 42

Subchronic neurotoxicity extrapolation of oral data to inhalation.ECA Appendix C .................................................................... 45

Developmental toxicity (oral) ............. 40 CFR 799.9370 (as annotated in ECA Appendix D.4) ...... 48

Developmental toxicity extrapolation

of oral data to inhalation.

ECA Appendix C .................................................................... 51

Reproductive toxicity (oral) ................ 40 CFR 799.9380 (as annotated in ECA Appendix D.5) ...... 54

Reproductive toxicity extrapolation of

oral data to inhalation.

ECA Appendix C .................................................................... 57

Immunotoxicity extrapolation of extant oral data in ECA Appendix E.2

to inhalation.

ECA Appendix C .................................................................... 33

Carcinogenicity extrapolation of extant oral data in ECA Appendix E.3

to inhalation.

ECA Appendix C .................................................................... 30

1Number of months after the effective date of the Order that incorporates this ECA when the final report is due. In addition, every 6 months

from the effective date of the Order until the end of the ECA testing program, interim reports describing the status of all testing to be performed

under this ECA must be submitted by the Companies to EPA.

C. What are the Uses for the Test Data

for TCE?

EPA will use the data obtained from

testing to implement several provisions

of section 112 of the Clean Air Act

(CAA), including the determination of

residual risk, the estimation of the risks

associated with accidental releases of

chemicals, and determinations whether

substances should be removed from the

CAA section 112(b)(1) list of hazardous

air pollutants (delisting). The data will

also be used by other Federal agencies

(e.g., the Agency for Toxic Substances

and Disease Registry (ATSDR), the

National Institute for Occupational

Safety and Health (NIOSH), the

Occupational Safety and Health

Administration (OSHA), and the

Consumer Product Safety Commission

(CPSC)) in assessing chemical risks and

in taking appropriate actions within

their programs. See the proposed HAPs

test rule published in the Federal

Register of June 26, 1996 (61 FR 33178,

33179) (FRL–4869–1).

D. Does the ECA for TCE Meet all the

Testing Requirements for TCE that were

Contained in the Proposed HAPs Test

Rule, as Amended?

In the proposed HAPs test rule, as

amended, EPA required testing of TCE

for acute toxicity, subchronic toxicity,

developmental toxicity, reproductive

toxicity, neurotoxicity, carcinogenicity,

in vivo cytogenetics, and

immunotoxicity by the inhalation route

of exposure. The ECA for TCE requires

testing for acute and subchronic toxicity

by inhalation, and developmental and

reproductive toxicity, and neurotoxicity

by oral exposure. This ECA does not

require testing for carcinogenicity,

immunotoxicity, or in vivo cytogenetics.

Instead, this ECA is requiring that PK/

MECH data and PBPK modeling be

developed in order to extrapolate

exposure by the oral route to the

inhalation route. These extrapolations

will be performed on extant data for

carcinogenicity and immunotoxicity

that have been determined to be

acceptable to EPA, as well as data which

will be developed under this ECA for

developmental and reproductive

toxicity and neurotoxicity.

The ECA does not require, and the

final HAPs test rule will not require, in

vivo cytogenetics testing because EPA

Federal Register / Vol. 65, No. 116 / Thursday, June 15, 2000 / Notices 37553

considers existing data to be sufficient

to fill the testing need identified in the

proposed HAPs test rule, as amended.

These data include a study by Mazzulo,

et al. (1986) demonstrating genotoxicity

and a study by Doherty, et al. (1996)

demonstrating cytogenicity, which are

included as appendices to the ECA

(Refs. 10,11). The Tier I HAPs Testing

endpoints will not be included in the

final HAPs test rule because such testing

will be conducted under this ECA.

Depending on the results of the EPA

Program Review, the Agency anticipates

that the balance of the testing for TCE

that was identified in the proposed

HAPs test rule, as amended, will also

not be included in the final HAPs test

rule because equivalent testing will be

conducted as Tier II Testing and

Extrapolation Reporting under this ECA.

The issuance of the ECA and Order

constitutes final EPA action for

purposes of 5 U.S.C. 704.

E. What if EPA Should Require

Additional Testing on TCE?

If EPA decides in the future that it

requires additional testing on TCE, the

Agency will initiate a separate action.

IV. Other Impacts of the ECA for TCE

The issuance of the ECA and Order

under TSCA section 4 subjects the

Companies that signed the ECA to

export notification requirements under

TSCA section 12(b)(1), as set forth at 40

CFR part 707, subpart D, if they export

or intend to export TCE.

In the Federal Register of December

23, 1997 (62 FR 67036) (FRL–5762–9),

EPA proposed to amend 40 CFR

799.5000 by adding TCE to the list of

chemicals subject to testing consent

orders. The listing of a chemical

substance at 40 CFR 799.5000 serves as

notification to all persons who export or

intend to export the chemical substance

that:

1. The chemical substance is the

subject of an ECA and Order.

2. EPA’s export notification

regulations at 40 CFR part 707, subpart

D, apply to those exporters who have

signed the ECA, as well as those

exporters who have not signed the ECA

(40 CFR 799.19).

When a final rule based on the

proposed rule is published in the

Federal Register, all persons who export

or who intend to export TCE will be

subject to export notification

requirements.

V. Text of the Testing Consent Order

As indicated in the ECA for TCE, EPA

is publishing the text of the Order in

this notice. The Order is entitled:

‘‘United States Environmental

Protection Agency; Testing Consent

Order for 1,1,2-Trichloroethane; Docket

No. OPPTS–42198C,’’ and reads as

follows:

‘‘Under the authority of section 4 of

the Toxic Substances Control Act

(TSCA), 15 U.S.C. 2603, the United

States Environmental Protection Agency

(EPA) issues this testing consent order

(Order) to take effect on the date of

publication of the notice in the Federal

Register announcing the issuance of this

Order. This Order incorporates the

enforceable consent agreement (ECA) for

1,1,2-Trichloroethane (TCE).’’

The Order was signed by Susan H.

Wayland, Acting Assistant

Administrator for Prevention, Pesticides

and Toxic Substances, on June 7, 2000.

VI. Paperwork Reduction Act

The ECA and Order announced in this

notice do not contain any information

collection requirements that require

additional approval by the Office of

Management and Budget (OMB) under

the Paperwork Reduction Act (PRA), 44

U.S.C. 3501 et seq. The information

collection requirements related to test

rules and ECAs issued under TSCA

section 4 have already been approved by

OMB under OMB control number 2070–

0033 (EPA ICR No. 1139). The one-time

public burden for this collection of

information is estimated to be

approximately 5,323 hours total. Under

the PRA, ‘‘burden’’ means the total time,

effort, or financial resources expended

by persons to generate, maintain, retain,

or disclose or provide information to or

for a Federal agency. For this collection

it includes the time needed to review

instructions; complete and review the

collection of information; and transmit

or otherwise disclose the information.

An agency may not conduct or sponsor,

and a person is not required to respond

to, a collection of information unless it

displays a currently valid OMB control

number. The OMB control numbers for

EPA’s regulations, after initial display in

the final rule, are listed in 40 CFR part

9.

VII. References

1. United States Environmental

Protection Agency (USEPA), OPPT.

TSCA Section 4 Findings for 21

Hazardous Air Pollutants: A Supporting

Document for Proposed Hazardous Air

Pollutants (HAPs) Test Rule. June 25,

1996.

2. The HAP Task Force. Letter from

Peter E. Voytek to Charles M. Auer with

attachment entitled: Proposal for

Pharmacokinetics Study of 1,1,2-

Trichloroethane, November 22, 1996.

November 22, 1996.

3. USEPA. Letter from Charles M.

Auer to Peter E. Voytek with attachment

entitled: Preliminary EPA Technical

Analysis of Proposed Industry

Pharmacokinetics (PK) Strategy for

1,1,2-Trichloroethane, June, 1997. June

26, 1997.

4. The HAP Task Force. Letter from

Peter E. Voytek to Charles M. Auer,

USEPA. December 12, 1997.

5. The HAP Task Force. Letter from

Peter E. Voytek to Charles M. Auer,

USEPA, with enclosure entitled:

Considerations for 1,1,2-TCE. February

27, 1998.

6. USEPA. Letter from Charles M.

Auer to Peter E. Voytek, HAP Task

Force, re: EPA final Position for ECA

Development of 1,1,2-Trichloroethane

(OPPTS –42198B), with attachment

entitled: DRAFT—1,1,2-TCE ECA—9/

23/98. September 24, 1998.

7. Final Enforceable Consent

Agreement for 1,1,2-Trichloroethane

and Accompanying Testing Consent

Order, signed by EPA on June 7, 2000.

8. Sanders, V. M., White, Jr., K. L.,

Shopp, Jr., G. M., and Musson, A.E.

Humoral and cell-mediated immune

status of mice exposed to 1,1,2-

trichloroethane. Drug and Chemical

Toxicology. 8(5):357–372. 1985.

9. National Cancer Institute (NCI).

Bioassay of 1,1,2-Trichloroethane for

Possible Carcinogenicity.

Carcinogenesis: Technical Report Series

No. 74. U.S. Department of Health,

Education and Welfare, Public Health

Service, National Institutes of Health.

1978.

10. Mazzullo, M., Colaccai, A., Grilli,

S., Prodi, G. and Arfellini, G. 1,1,2-

trichloroethane: evidence of

genotoxicity from short-term tests.

Japanese Journal of Cancer Research.

77:532–539. 1986.

11. Doherty, A.T., Ellard, S., Parry,

E.M., and Parry, J.M. An investigation

into the activation and deactivation of

chlorinated hydrocarbons to genotoxins

in metabolically competent human

cells. Mutagenesis. 11(3):247–274. 1996.

List of Subjects

Environmental protection, Hazardous

chemicals.

Dated: June 7, 2000.

Susan H. Wayland,

Acting Assistant Administrator for

Prevention, Pesticides and Toxic Substances.

[FR Doc. 00–15162 Filed 6–14–00; 8:45 am]

BILLING CODE 6560–50–F